In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Catalyst Pharmaceuticals, Inc.. Trade Record

NASDAQ:CPRX Catalyst Pharmaceuticals, Inc. stock gains 10.86% Exit Feb 28, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart CPRX Feb 8, 2019, priceSeries
About Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. Its lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in second Phase III clinical trials for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as well as is in Phase II/III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis. The company also develops CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor that is in Phase Ib clinical trial for the treatment of epilepsy, infantile spams, and Tourette's disorder; and CPP-109 to treat Tourette's disorder. It has a strategic collaboration with BioMarin Pharmaceutical Inc. for the development of Firdapse. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Trade Information
Trade Type
LONG
ReliabilityScore™
91.02
Entry Date
Feb 8, 2019
Entry Price
2.47
Sell Date
Feb 28, 2019
Sell Price
2.74
Net Gain
10.86%
Hold Time
13 Trading Days